AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29909789 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD-11PGD guideline
Number of subjects: 261
Study 29909789 — intervention group
Group type: COMPARATOR
Intervention: PGDPLOS criteria
Number of subjects: 261
Study 29282259 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (6-month weekly exercise program, 60 min, two times a week)
Number of subjects: 83
Study 29282259 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 83
Study 27720650 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric with black pepper
Number of subjects: 40
Study 27720650 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa
Number of subjects: 40
Study 24682379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 7002
Study 24682379 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 7002
Study 22585232 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 7.5 mg
Number of subjects: 0
Study 22585232 — intervention group
Group type: EXPERIMENTAL
Intervention: THC 15 mg
Number of subjects: 0
Study 22585232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22585232 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (both doses)
Number of subjects: 0
Study 22585232 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 0
Study 18560873 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone sodium phosphate 0.1% with neomycin sulphate 0.5% (Vista‐Methasone N)
Number of subjects: 45
Study 18560873 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone sodium phosphate 0.1% (Vista‐Methasone)
Number of subjects: 45
Study 17446010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus melatonin (20 mg/day orally in the evening)
Number of subjects: 370
Study 17446010 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 370
Study 15220952 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine enriched with alpha-linolenic acid (ALA) for 2 years
Number of subjects: 103
Study 15220952 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid (LA) margarine for 2 years
Number of subjects: 103
Study 11462311 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy after a 12-week period with enhanced compliance to diet and oral therapy
Number of subjects: 38
Study 11462311 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy as soon as secondary failure was established
Number of subjects: 38
Study 11462311 — intervention group
Group type: COMPARATOR
Intervention: Enhanced compliance to diet and oral therapy (control group)
Number of subjects: 38
Study 9787691 — intervention group
Group type: COMPARATOR
Intervention: Depo-testosterone (to boys) or conjugated estrogens (to girls) administered in 3-month blocks, alternating with placebo, at 3 dose levels.
Number of subjects: 55
Study 9787691 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group) administered in 3-month blocks, alternating with Depo-testosterone or conjugated estrogens.
Number of subjects: 55
Study 7633988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline infusion therapy, 600 mg twice daily for up to 21 days
Number of subjects: 314
Study 7633988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin in conjunction with aspirin and a thrombolytic agent
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists or antiarrhythmic agents
Number of subjects: 0
Study 1975522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasodilators
Number of subjects: 0
Study 896123 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (20‐25 mg/m2/day for three days each three weeks)
Number of subjects: 22
Study 31188260 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment for intra-articular DRF based on patient factors such as younger age, clinically significant fracture displacement, normal activity level, and high-energy mechanisms.
Number of subjects: 224
Study 31188260 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon factors recommending surgery, including practicing outside the United States.
Number of subjects: 224
Study 31188260 — intervention group
Group type: COMPARATOR
Intervention: Treatment decisions rated by AUC recommendations.
Number of subjects: 224
Study 27839722 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (10 Hz)
Number of subjects: 24
Study 27839722 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 26037400 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation for 8 weeks
Number of subjects: 31
Study 26037400 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 31
Study 24274589 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic transluminal step-up approach
Number of subjects: 98
Study 24274589 — intervention group
Group type: COMPARATOR
Intervention: Surgical step-up approach
Number of subjects: 98
Study 21923016 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 105
Study 21923016 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction
Number of subjects: 105
Study 19140167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-[(123)I]IA administered intravenously at approximately 0.001 microg/kg (approximately 10 mCi)
Number of subjects: 12
Study 19140167 — intervention group
Group type: COMPARATOR
Intervention: High plasma-nicotine levels
Number of subjects: 12
Study 17184672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 16
Study 17184672 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 16
Study 15010644 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 10439
Study 15010644 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 10439
Study 11829098 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler; 90 microg delivered dose; 120 microg metered dose)
Number of subjects: 48
Study 11829098 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (Bricanyl Turbuhaler; 10 mg)
Number of subjects: 48
Study 11829098 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler; 90 microg)
Number of subjects: 48
Study 10431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanic equipment operators
Number of subjects: 341
Study 10431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranemen
Number of subjects: 341
Study 10431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Container stevedores
Number of subjects: 341
Study 10431650 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoistmen
Number of subjects: 341
Study 10431650 — intervention group
Group type: COMPARATOR
Intervention: Control group (Electricians)
Number of subjects: 341
Study 10431650 — intervention group
Group type: EXPERIMENTAL
Intervention: All examined workers
Number of subjects: 341
Study 8282977 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (12-exercise circuit, 3 sets of 8 repetitions at 75% of 1-RM), 3 times a week
Number of subjects: 25
Study 8282977 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 25
Study 8282977 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary, no exercise program)
Number of subjects: 25
Study 2178939 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin weekly for 6 weeks followed by no further treatment (short-term regimen)
Number of subjects: 146
Study 2178939 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin weekly for 6 weeks followed by monthly instillation for 2 years (long-term regimen)
Number of subjects: 146
Study 72901 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker alone
Number of subjects: 7
Study 72901 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 72901 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker plus indomethacin (100 mg daily)
Number of subjects: 7
Study 72901 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker alone (last phase)
Number of subjects: 7
Study 31562765 — intervention group
Group type: EXPERIMENTAL
Intervention: SGM-tailored Facebook intervention (POP)
Number of subjects: 165
Study 31562765 — intervention group
Group type: COMPARATOR
Intervention: Non-tailored intervention (TSP-SGM)
Number of subjects: 165
Study 29338320 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month group medical clinic intervention
Number of subjects: 239
Study 29338320 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month group medical clinic intervention stratified by >0.5% reduction in hemoglobin A1c
Number of subjects: 239
Study 29338320 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 239
Study 29338320 — intervention group
Group type: COMPARATOR
Intervention: usual care stratified by >0.5% reduction in hemoglobin A1c
Number of subjects: 239
Study 28420471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pv‐aCO2 combined with PLR directed therapy
Number of subjects: 80
Study 28420471 — intervention group
Group type: COMPARATOR
Intervention: Central venous pressure (CVP) directed therapy
Number of subjects: 80
Study 25189089 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone treatment
Number of subjects: 252
Study 25189089 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use disorder treatment (most commonly opioid agonist therapy)
Number of subjects: 252
Study 25189089 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain severity
Number of subjects: 252
Study 22092589 — intervention group
Group type: EXPERIMENTAL
Intervention: NobelActive(TM) implant
Number of subjects: 32
Study 22092589 — intervention group
Group type: COMPARATOR
Intervention: Brånemark implant
Number of subjects: 32
Study 17021415 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum Cobb angle technique
Number of subjects: 30
Study 17021415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangent circles technique
Number of subjects: 30
Study 17021415 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 30
Study 14534586 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on a small set of words
Number of subjects: 0
Study 14534586 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0
Study 14534586 — intervention group
Group type: COMPARATOR
Intervention: Retention interval without sleep
Number of subjects: 0
Study 10224729 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 96
Study 10224729 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 96
Study 10224729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (PE-SIT)
Number of subjects: 96
Study 10224729 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 96
Study 8722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 60 mg/day
Number of subjects: 31
Study 8722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 200 mg/day
Number of subjects: 31
Study 8722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol 15 mg/day
Number of subjects: 31
Study 8722217 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 31
Study 8722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (all dosages)
Number of subjects: 31
Study 1848679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ganciclovir (5 mg/kg IV twice daily for two weeks, then five times per week until day 120)
Number of subjects: 40
Study 1848679 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (control group)
Number of subjects: 40
Study 1848679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic ganciclovir
Number of subjects: 40
Study 1848679 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-negative patients
Number of subjects: 40
Study 6404377 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime administration of intermediate acting insulin
Number of subjects: 6
Study 6404377 — intervention group
Group type: COMPARATOR
Intervention: Conventional twice daily insulin regimen
Number of subjects: 6
Study 31473600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L/min for 6-12 hours
Number of subjects: 5010
Study 31473600 — intervention group
Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 5010
Study 31473600 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 5010
Study 29296829 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet alfa
Number of subjects: 60
Study 29296829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26006195 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L)
Number of subjects: 118
Study 26006195 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus Benzydamine (LB)
Number of subjects: 118
Study 26006195 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine (B)
Number of subjects: 118
Study 23083421 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised insoles
Number of subjects: 38
Study 23083421 — intervention group
Group type: COMPARATOR
Intervention: Control insoles
Number of subjects: 38
Study 20530054 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g fibrinogen concentrate
Number of subjects: 20
Study 20530054 — intervention group
Group type: COMPARATOR
Intervention: No infusion (control group)
Number of subjects: 20
Study 19850684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogens (CEE) daily
Number of subjects: 886
Study 19850684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 886
Study 17178700 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alpha-lipoic acid, 600 mg twice daily for 4 weeks
Number of subjects: 12
Study 17178700 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal glucose tolerance)
Number of subjects: 12
Study 12932748 — intervention group
Group type: COMPARATOR
Intervention: Growth Hormone (GH) treatment (Genotropin, Pharmacia) starting at 0.8 IU for one month, then 1.6 IU for 5 months, followed by individual titration to normal levels for age.
Number of subjects: 17
Study 12932748 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment.
Number of subjects: 17
Study 11101059 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily stavudine (40 mg) plus once-daily didanosine (400 mg) and nevirapine (400 mg)
Number of subjects: 94
Study 11101059 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily stavudine (40 mg) plus twice-daily didanosine (200 mg) and nevirapine (200 mg)
Number of subjects: 94
Study 8985029 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and razoxane (150 mg/m2 daily during radiotherapy, starting 5 days before first irradiation)
Number of subjects: 130
Study 8985029 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 130
Study 8985029 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and razoxane
Number of subjects: 130
Study 1451518 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-plated uterine cavity-shaped IUD (UCDcu)
Number of subjects: 0
Study 1451518 — intervention group
Group type: COMPARATOR
Intervention: Uterine cavity-shaped stainless steel IUD (UCD)
Number of subjects: 0
Study 1451518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IUDs (UCDcu and UCD)
Number of subjects: 0
Study 6372024 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotics
Number of subjects: 127
Study 6372024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 30802762 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer-specific fatigue protocol
Number of subjects: 10
Study 29454318 — intervention group
Group type: EXPERIMENTAL
Intervention: Points-based physical activity (PBPA; 30 'PA points'•week‐1)
Number of subjects: 76
Study 29454318 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT; continue habitual inactive lifestyle)
Number of subjects: 76
Study 26810282 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with HDM allergen extract
Number of subjects: 50
Study 26810282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24971785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate alone
Number of subjects: 56
Study 24971785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate and Metformin
Number of subjects: 56
Study 21782542 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral high-frequency rTMS (20 Hz) administered daily for 4 weeks (total of 20 treatments)
Number of subjects: 25
Study 21782542 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 25
Study 21149920 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg quantification
Number of subjects: 289
Study 21149920 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon treatment
Number of subjects: 289
Study 21149920 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 289
Study 16979255 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 24
Study 16979255 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 24
Study 15692345 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort III osteotomy
Number of subjects: 31
Study 15692345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 31
Study 12382459 — intervention group
Group type: EXPERIMENTAL
Intervention: APN intervention
Number of subjects: 32
Study 12382459 — intervention group
Group type: COMPARATOR
Intervention: No APN intervention (Control)
Number of subjects: 32
Study 9923817 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron daily plus 300 mg cimetidine four times daily
Number of subjects: 18
Study 9923817 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg dolasetron daily plus 600 mg rifampin daily
Number of subjects: 18
Study 9923817 — intervention group
Group type: COMPARATOR
Intervention: 200 mg dolasetron daily (control)
Number of subjects: 18
Study 7578795 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier membrane alone
Number of subjects: 19
Study 7578795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone allograft with barrier membrane
Number of subjects: 19
Study 2254674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20‐40 mg three times a day)
Number of subjects: 40
Study 2254674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2254674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 40
Study 7000089 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (5 g X 3)
Number of subjects: 22
Study 7000089 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol (15 g daily) divided into 1, 2 or 3 daily doses
Number of subjects: 22
Study 7000089 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol hydrochloride (15 g daily)
Number of subjects: 22
Study 7000089 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol treatment
Number of subjects: 22
Study 31948475 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpishengsui (JPSS) herbal formula cream, 15g orally, twice a day from day 6 to day 20 during chemotherapy.
Number of subjects: 0
Study 31948475 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice a day from day 6 to day 20 during chemotherapy.
Number of subjects: 0
Study 31948475 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpishengsui (JPSS) herbal formula cream
Number of subjects: 0
Study 31948475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31948475 — intervention group
Group type: EXPERIMENTAL
Intervention: Jianpishengsui (JPSS) herbal formula cream and Placebo
Number of subjects: 0
Study 31684903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led guided participation discharge intervention (three structured 30- to 60-min GP sessions and one follow-up phone call)
Number of subjects: 30
Study 31684903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led guided participation discharge intervention
Number of subjects: 30
Study 31684903 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 28806820 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic training
Number of subjects: 17
Study 28806820 — intervention group
Group type: COMPARATOR
Intervention: Computer-based self-learning
Number of subjects: 17
Study 25814356 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (PCI)
Number of subjects: 216
Study 25814356 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (ischemia-guided)
Number of subjects: 216
Study 23968283 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation over the left supramarginal gyrus
Number of subjects: 0
Study 23968283 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (control group)
Number of subjects: 0
Study 23968283 — intervention group
Group type: COMPARATOR
Intervention: Visual memory control task
Number of subjects: 0
Study 21853543 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-hyperintensities on brain MRI
Number of subjects: 162
Study 21853543 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without NF1)
Number of subjects: 162